RTW Biotech Opportunities joins $160.5m Series C of Obsidian Therapeutics
RTW Biotech Opportunities Ltd, an investment company listed on the London Stock Exchange and specialized in the life sciences sector, is proud to announce its ... Read More
OncoSec Medical begins phase 2 trial for TAVO and OPDIVO combination in melanoma treatment
OncoSec Medical, a US-based biotechnology company, has officially dosed the first patient in its phase 2 clinical trial, OMS-104, aimed at evaluating the combination of ... Read More